Integrated Filing — IndAS
General information about company
| Scrip Code |
540975 |
| NSE Symbol |
ASTERDM |
| MSEI Symbol |
NOTLISTED |
| ISIN |
INE914M01019 |
| Name of company |
ASTER DM HEALTHCARE LIMITED |
| Type of company |
Main Board |
| Class of security |
Equity |
| Date of start of financial year |
01-04-2025 |
| Date of end of financial year |
31-03-2026 |
| Date of board meeting when results were approved |
30-01-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed
to the exchange |
23-01-2026 |
| Description of presentation currency |
INR |
| Level of rounding used in financial results |
Lakhs |
| Reporting Type |
Quarterly |
| Reporting Quarter |
Third quarter |
| Nature of report standalone or consolidated |
Consolidated |
| Whether results are audited or unaudited for the quarter ended |
Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended |
Unaudited |
| Segment Reporting |
Multi segment |
| Description of single segment |
|
| Start date and time of board meeting |
30-01-2026 12:15:00 |
| End date and time of board meeting |
30-01-2026 18:20:00 |
| Whether cash flow statement is applicable on company |
|
| Type of cash flow statement |
|
| Declaration of unmodified opinion or statement on impact of audit qualification |
|
Financial Results Ind-AS
Amount in (Lakhs)
| Particulars |
3 months/ 6 months ended (dd-mm-yyyy) |
Year to date figures for current period ended (dd-mm-yyyy) |
| A |
Date of start of reporting period |
01-10-2025 |
01-04-2025 |
| B |
Date of end of reporting period |
31-12-2025 |
31-12-2025 |
| C |
Whether results are audited or unaudited |
Unaudited |
Unaudited |
| D |
Nature of report standalone or consolidated |
Consolidated |
Consolidated |
| 1 |
Income |
|
Revenue from operations |
1,18,576.00 |
3,46,084.00 |
|
Other income |
2,797.00 |
8,940.00 |
|
Total income |
1,21,373.00 |
3,55,024.00 |
| 2 |
Expenses |
| (a) |
Cost of materials consumed |
0.00 |
0.00 |
| (b) |
Purchases of stock-in-trade |
27,044.00 |
78,864.00 |
| (c) |
Changes in inventories of finished goods,
work-in-progress and stock-in-trade |
(296.00) |
(301.00) |
| (d) |
Employee benefit expense |
22,137.00 |
62,810.00 |
| (e) |
Finance costs |
3,146.00 |
9,299.00 |
| (f) |
Depreciation, depletion and amortisation expense
|
6,767.00 |
19,701.00 |
| (f) |
Other Expenses |
| 1 |
Professional fees to consultant doctors |
27,036.00 |
76,721.00 |
| 2 |
Laboratory outsourcing charges |
828.00 |
2,217.00 |
| 3 |
Other expenses |
20,702.00 |
58,928.00 |
| 4 |
0 |
0.00 |
0.00 |
| 5 |
0 |
0.00 |
0.00 |
| 6 |
0 |
0.00 |
0.00 |
| 7 |
0 |
0.00 |
0.00 |
| 8 |
0 |
0.00 |
0.00 |
| 9 |
0 |
0.00 |
0.00 |
| 10 |
0 |
0.00 |
0.00 |
|
Total other expenses |
48,566.00 |
1,37,866.00 |
|
Total expenses |
1,07,364.00 |
3,08,239.00 |
| 3 |
Total profit before exceptional items and tax |
14,009.00 |
46,785.00 |
| 4 |
Exceptional items |
(2,829.00) |
(3,304.00) |
| 5 |
Total profit before tax |
11,180.00 |
43,481.00 |
| 6 |
Tax expense |
|
| 7 |
Current tax |
5,914.00 |
14,966.00 |
| 8 |
Deferred tax |
(1,474.00) |
(1,684.00) |
| 9 |
Total tax expenses |
4,440.00 |
13,282.00 |
| 10 |
Net movement in regulatory deferral account balances related to profit or loss and
the related deferred tax movement |
0.00 |
0.00 |
| 11 |
Net Profit Loss for the period from
continuing operations |
6,740.00 |
30,199.00 |
| 12 |
Profit (loss) from discontinued operations before tax |
0.00 |
0.00 |
| 13 |
Tax expense of discontinued operations |
0.00 |
0.00 |
| 14 |
Net profit (loss) from discontinued
operation after tax |
0.00 |
0.00 |
| 15 |
Share of profit (loss) of associates and joint ventures accounted for using equity
method |
(875.00) |
(2,847.00) |
| 16 |
Total profit (loss) for period |
5,865.00 |
27,352.00 |
| 17 |
Other comprehensive income net of taxes |
(205.00) |
(224.00) |
| 18 |
Total Comprehensive Income for the period |
5,660.00 |
27,128.00 |
| 19 |
Total profit or loss, attributable to
|
|
|
|
Profit or loss, attributable to owners of parent |
5,245.00 |
24,797.00 |
|
Total profit or loss, attributable to non-controlling interests |
620.00 |
2,555.00 |
| 20 |
Total Comprehensive income for the period attributable to |
|
|
|
Comprehensive income for the period attributable to owners of parent |
5,063.00 |
24,596.00 |
|
Total comprehensive income for the period attributable to owners of parent non-controlling
interests |
597.00 |
2,532.00 |
| 21 |
Details of equity share capital |
|
|
Paid-up equity share capital |
51,813.00 |
51,813.00 |
|
Face value of equity share capital |
10 |
10 |
| 27 |
Details of debt securities |
|
| 22 |
Reserves excluding revaluation reserve |
|
|
| 23 |
Earnings per share |
|
| i |
Earnings per equity share for continuing operations |
|
|
Basic earnings (loss) per share from continuing operations |
1.02 |
4.82 |
|
Diluted earnings (loss) per share from continuing operations |
1.02 |
4.81 |
| ii |
Earnings per equity share for discontinued operations |
|
|
Basic earnings (loss) per share from discontinued operations |
0 |
0 |
|
Diluted earnings (loss) per share from discontinued operations |
0 |
0 |
| ii |
Earnings per equity share |
|
|
Basic earnings (loss) per share from continuing
and discontinued operations |
1.02 |
4.82 |
|
Diluted earnings (loss) per share from
continuing and discontinued operations |
1.02 |
4.81 |
| 24 |
Debt equity ratio |
|
|
| 25 |
Debt service coverage ratio |
|
|
| 26 |
Interest service coverage ratio |
|
|
| 27 |
Disclosure of notes on financial results |
|
Remarks
Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results
Amount in (Lakhs)
| Particulars |
3 months/ 6 month ended (dd-mm-yyyy) |
Year to date figures for current period
ended (dd-mm-yyyy) |
| Date of start of reporting period |
01-10-2025 |
01-04-2025 |
| Date of end of reporting
period |
31-12-2025 |
31-12-2025 |
| Whether results are audited
or unaudited |
Unaudited |
Unaudited |
| Nature of report standalone or
consolidated |
Consolidated |
Consolidated |
| 1 |
Segment Revenue (Income) |
|
(net sale/income from each segment should
be disclosed) |
| 1 |
Hospitals |
1,15,486.00 |
3,36,642.00 |
| 2 |
Clinics |
0.00831 |
2,307.00 |
| 3 |
Wholesale Pharmacies |
2,041.00 |
6,226.00 |
| 4 |
Others |
0.00218 |
0.00909 |
| 5 |
0 |
0.00 |
0.00 |
| 6 |
0 |
0.00 |
0.00 |
| 7 |
0 |
0.00 |
0.00 |
| 8 |
0 |
0.00 |
0.00 |
| 9 |
0 |
0.00 |
0.00 |
| 10 |
0 |
0.00 |
0.00 |
| 11 |
0 |
0.00 |
0.00 |
| 12 |
0 |
0.00 |
0.00 |
| 13 |
0 |
0.00 |
0.00 |
| 14 |
0 |
0.00 |
0.00 |
| 15 |
0 |
0.00 |
0.00 |
|
Total Segment Revenue |
1,18,576.00 |
3,46,084.00 |
|
Less: Inter segment revenue |
0.00 |
0.00 |
|
Revenue from operations |
1,18,576.00 |
3,46,084.00 |
| 2 |
Segment Result |
|
Profit (+) / Loss (-) before tax and
interest from each segment |
| 1 |
Hospitals |
19,794.00 |
61,639.00 |
| 2 |
Clinics |
(102.00) |
(510.00) |
| 3 |
Wholesale Pharmacies |
(778.00) |
(2,514.00) |
| 4 |
Others |
(448.00) |
(1,644.00) |
| 5 |
0 |
0.00 |
0.00 |
| 6 |
0 |
0.00 |
0.00 |
| 7 |
0 |
0.00 |
0.00 |
| 8 |
0 |
0.00 |
0.00 |
| 9 |
0 |
0.00 |
0.00 |
| 10 |
0 |
0.00 |
0.00 |
| 11 |
0 |
0.00 |
0.00 |
| 12 |
0 |
0.00 |
0.00 |
| 13 |
0 |
0.00 |
0.00 |
| 14 |
0 |
0.00 |
0.00 |
| 15 |
0 |
0.00 |
0.00 |
|
Total Profit before tax |
18,466.00 |
56,971.00 |
|
i. Finance cost |
3,146.00 |
9,299.00 |
|
ii. Other Unallocable Expenditure net off Unallocable income |
5,015.00 |
7,038.00 |
|
Profit before tax |
10,305.00 |
40,634.00 |
| 3 |
(Segment Asset - Segment Liabilities)
|
|
Segment Asset |
| 1 |
Hospitals |
6,54,331.00 |
6,54,331.00 |
| 2 |
Clinics |
1,693.00 |
1,693.00 |
| 3 |
Wholesale Pharmacies |
5,967.00 |
5,967.00 |
| 4 |
Others |
2,603.00 |
2,603.00 |
| 5 |
0 |
0.00 |
0.00 |
| 6 |
0 |
0.00 |
0.00 |
| 7 |
0 |
0.00 |
0.00 |
| 8 |
0 |
0.00 |
0.00 |
| 9 |
0 |
0.00 |
0.00 |
| 10 |
0 |
0.00 |
0.00 |
| 11 |
0 |
0.00 |
0.00 |
| 12 |
0 |
0.00 |
0.00 |
| 13 |
0 |
0.00 |
0.00 |
| 14 |
0 |
0.00 |
0.00 |
| 15 |
0 |
0.00 |
0.00 |
|
Total Segment Asset |
6,64,594.00 |
6,64,594.00 |
|
Un-allocable Assets |
1,24,832.00 |
1,24,832.00 |
|
Net Segment Asset |
7,89,426.00 |
7,89,426.00 |
| 4 |
Segment Liabilities |
|
Segment Liabilities |
| 1 |
Hospitals |
2,95,491.00 |
2,95,491.00 |
| 2 |
Clinics |
943.00 |
943.00 |
| 3 |
Wholesale Pharmacies |
1,936.00 |
1,936.00 |
| 4 |
Others |
0.00 |
0.00 |
| 5 |
0 |
0.00 |
0.00 |
| 6 |
0 |
0.00 |
0.00 |
| 7 |
0 |
0.00 |
0.00 |
| 8 |
0 |
0.00 |
0.00 |
| 9 |
0 |
0.00 |
0.00 |
| 10 |
0 |
0.00 |
0.00 |
| 11 |
0 |
0.00 |
0.00 |
| 12 |
0 |
0.00 |
0.00 |
| 13 |
0 |
0.00 |
0.00 |
| 14 |
0 |
0.00 |
0.00 |
| 15 |
0 |
0.00 |
0.00 |
|
Total Segment Liabilities |
2,98,370.00 |
2,98,370.00 |
|
Un-allocable Liabilities |
8,040.00 |
8,040.00 |
|
Net Segment Liabilities |
3,06,410.00 |
3,06,410.00 |
|
Disclosure of notes on segments |
|
Other Comprehensive Income
Amount in (Lakhs)
| Particulars |
3 months/ 6 months ended (dd-mm-yyyy) |
Year to date figures for current period ended (dd-mm-yyyy) |
| A |
Date of start of reporting period |
01-10-2025 |
01-04-2025 |
| B |
Date of end of reporting period |
31-12-2025 |
31-12-2025 |
| C |
Whether results are audited or unaudited |
Unaudited |
Unaudited |
| D |
Nature of report standalone or consolidated |
Consolidated |
Consolidated |
|
Other comprehensive income [Abstract] |
|
| 1 |
Amount of items that will not be reclassified to profit and loss |
|
| 1 |
Remeasurement of net defined benefit liability |
(294.00) |
(294.00) |
|
Total Amount of items that will not be reclassified to profit and loss |
(294.00) |
(294.00) |
| 2 |
Income tax relating to items that will not be reclassified to profit or loss |
(70.00) |
(70.00) |
| 3 |
Amount of items that will be reclassified to profit and loss |
|
| 1 |
Exchange difference in translating financial statements of foreign operations |
25.00 |
0.00 |
|
Total Amount of items that will be reclassified to profit and loss |
25.00 |
0.00 |
| 4 |
Income tax relating to items that will be reclassified to profit or loss |
6.00 |
0.00 |
| 5 |
Total Other comprehensive income |
(205.00) |
(224.00) |
Details of Impact of Audit Qualification
Amount in (Lakhs)
| Whether results are audited or unaudited |
|
| Declaration of unmodified opinion or statement on impact of audit qualification |
|
| Auditor's opinion |
|
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015:
The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified
opinion for the period on Standalone results |
|
| Sr No. |
Audit firm's name |
Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI |
Certificate valid upto |